Ozempic not tied to pancreatic cancer risk, study suggests

Ozempic and other glucagon-like peptide-1 receptor agonists are not linked to a higher risk of pancreatic cancer compared to insulin, according to a recent study

GLP-1s approved for Type 2 diabetes, including Ozempic, Trulicity and Rybelsus, have faced regulatory scrutiny for a range of side effects such as hair loss, aspiration and suicidal thoughts. A potential connection between GLP-1s and pancreatic cancer, though, was suggested to be unfounded in an Israel-based study of more than 500,000 adult patients.

Between 2009 — when GLP-1s became available in Israel — and 2017, the hazard risk for developing pancreatic cancer was similar among diabetes patients who took insulin compared to GLP-1 users. The risk rate for GLP-1s was 0.52, and insulin's risk rate was 0.75, according to the study. 

About 33,000 patients took a GLP-1 and 106,000 used basal insulin. Of the 543,595 patient records part of the study, 1,665, or 0.31%, of the records indicated a pancreatic cancer diagnosis. 

The researchers concluded the safety risk was not supported, but said monitoring for pancreatic cancer risk beyond seven years is still required.

The results were published Jan. 4 in JAMA.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like